Merit Medical Stock Soars After Hours As Better-Than-Expected Q2 Guidance Outweighs CEO Exit

Merit Medical shares edged higher in Monday’s after-hours session after the company guided to stronger-than-expected revenue for the second quarter and outlined plans for a new CEO later this year.

The company rose 3.2% after hours to $94.01, trimming losses from the regular session, where it closed down 2.6% at $91.12.

For the three months through June, Merit estimates revenue between $380 million and $384 million, representing a 12% to 14% increase from the same period last year. 

Adjusting for currency fluctuations, the company expects growth to range between 11% and 13%, with approximately $2.3 million in revenue being shaved off due to exchange rate impacts. A year earlier, Merit posted $338 million in revenue. 

The latest results exceeded analysts’ expectations, which had projected a figure of $372.47 million. A leadership handoff is also scheduled for later this year. 

On Oct. 3, Martha Aronson is set to take over as president and CEO, replacing Fred P. Lampropoulos, who will continue as chairman of the board. The transition follows a board-led selection process. 

Lampropoulos will remain in his current executive role until the transition date. Aronson held senior roles at Ecolab and Hill-Rom Holdings, and spent nearly 20 years at Medtronic, managing business operations in both domestic and global markets. 

She has also served on the boards of several healthcare and medtech firms, including Conmed Corporation, where she was chair, as well as Methode Electronics and Cardiovascular Systems, Inc.

On Stocktwits, the retail sentiment for MMIS stock was ‘neutral’ amid ‘low’ message volume late Monday.

Merit Medical’s stock has declined 5.2% so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.